Feralgine™ a New Approach for Iron Deficiency Anemia in Celiac Patients
Background: Celiac disease (CD) is an immunologically-mediated disorder characterized by duodenal mucosa villi atrophy. Iron absorption is usually reduced in celiac patients making every kind of oral iron treatment unhelpful because of malasorption. Feralgine™ is a new product that has bee...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-04-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/11/4/887 |
| _version_ | 1811266596226727936 |
|---|---|
| author | Laura Giancotti Valentina Talarico Giuseppe Antonio Mazza Santina Marrazzo Pietro Gangemi Roberto Miniero Marco Bertini |
| author_facet | Laura Giancotti Valentina Talarico Giuseppe Antonio Mazza Santina Marrazzo Pietro Gangemi Roberto Miniero Marco Bertini |
| author_sort | Laura Giancotti |
| collection | DOAJ |
| description | Background: Celiac disease (CD) is an immunologically-mediated disorder characterized by duodenal mucosa villi atrophy. Iron absorption is usually reduced in celiac patients making every kind of oral iron treatment unhelpful because of malasorption. Feralgine™ is a new product that has been demonstrated to be more bioavailable. As such, the aim of our study was to evaluate the absorption of Feralgine™ in adult patients with CD. Methods: Twenty-six adults affected by Iron Deficiency Anemia (IDA), of which 14 were also affected by CD and 12 were not affected by CD, were enrolled. An oral iron absorption test (OIAT) was performed in each patient by administrating Feralgine™, and serum iron was evaluated at baseline (T0) and after 2 h (T1) from the oral iron ingestion. Results: The OIAT was well tolerated in all patients, and, surprisingly, an equivalent statistically significant improvement in serum iron occurred in the two groups of patients (IDA plus CD: T0 = 28.21 µg/dL vs. T1 = 94.14 µg/dL <i>p</i> = 0.004 and IDA without CD: T0 = 34.91 µg/dL vs. T1 = 118.83 µg/dL, <i>p</i> = 0.0003). Conclusions: These results demonstrated the high absorption of Feralgine™ in celiac patients, confirming our previous data obtained with Ferrous Bysglicinate in children with CD. |
| first_indexed | 2024-04-12T20:46:04Z |
| format | Article |
| id | doaj.art-8f8abf15fd934ad48352af4f9dfa501a |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-04-12T20:46:04Z |
| publishDate | 2019-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-8f8abf15fd934ad48352af4f9dfa501a2022-12-22T03:17:16ZengMDPI AGNutrients2072-66432019-04-0111488710.3390/nu11040887nu11040887Feralgine™ a New Approach for Iron Deficiency Anemia in Celiac PatientsLaura Giancotti0Valentina Talarico1Giuseppe Antonio Mazza2Santina Marrazzo3Pietro Gangemi4Roberto Miniero5Marco Bertini6Department of Pediatrics, Pugliese-Ciaccio Hospital-Magna Graecia University, 88100 Catanzaro, ItalyDepartment of Pediatrics, Pugliese-Ciaccio Hospital-Magna Graecia University, 88100 Catanzaro, ItalyDepartment of Pediatrics, Pugliese-Ciaccio Hospital-Magna Graecia University, 88100 Catanzaro, ItalyDepartment of Pediatrics, Pugliese-Ciaccio Hospital-Magna Graecia University, 88100 Catanzaro, ItalyClinical Chemistry Laboratory, Pugliese-Ciaccio Hospital, 88100 Catanzaro, ItalyDepartment of Pediatrics, Pugliese-Ciaccio Hospital-Magna Graecia University, 88100 Catanzaro, ItalyR&D Department, Laboratori Baldacci SpA, 56124 Pisa, ItalyBackground: Celiac disease (CD) is an immunologically-mediated disorder characterized by duodenal mucosa villi atrophy. Iron absorption is usually reduced in celiac patients making every kind of oral iron treatment unhelpful because of malasorption. Feralgine™ is a new product that has been demonstrated to be more bioavailable. As such, the aim of our study was to evaluate the absorption of Feralgine™ in adult patients with CD. Methods: Twenty-six adults affected by Iron Deficiency Anemia (IDA), of which 14 were also affected by CD and 12 were not affected by CD, were enrolled. An oral iron absorption test (OIAT) was performed in each patient by administrating Feralgine™, and serum iron was evaluated at baseline (T0) and after 2 h (T1) from the oral iron ingestion. Results: The OIAT was well tolerated in all patients, and, surprisingly, an equivalent statistically significant improvement in serum iron occurred in the two groups of patients (IDA plus CD: T0 = 28.21 µg/dL vs. T1 = 94.14 µg/dL <i>p</i> = 0.004 and IDA without CD: T0 = 34.91 µg/dL vs. T1 = 118.83 µg/dL, <i>p</i> = 0.0003). Conclusions: These results demonstrated the high absorption of Feralgine™ in celiac patients, confirming our previous data obtained with Ferrous Bysglicinate in children with CD.https://www.mdpi.com/2072-6643/11/4/887oral iron absorption testceliac diseaseferrous bisglycinate chelate alginateiron deficiency anemia |
| spellingShingle | Laura Giancotti Valentina Talarico Giuseppe Antonio Mazza Santina Marrazzo Pietro Gangemi Roberto Miniero Marco Bertini Feralgine™ a New Approach for Iron Deficiency Anemia in Celiac Patients Nutrients oral iron absorption test celiac disease ferrous bisglycinate chelate alginate iron deficiency anemia |
| title | Feralgine™ a New Approach for Iron Deficiency Anemia in Celiac Patients |
| title_full | Feralgine™ a New Approach for Iron Deficiency Anemia in Celiac Patients |
| title_fullStr | Feralgine™ a New Approach for Iron Deficiency Anemia in Celiac Patients |
| title_full_unstemmed | Feralgine™ a New Approach for Iron Deficiency Anemia in Celiac Patients |
| title_short | Feralgine™ a New Approach for Iron Deficiency Anemia in Celiac Patients |
| title_sort | feralgine™ a new approach for iron deficiency anemia in celiac patients |
| topic | oral iron absorption test celiac disease ferrous bisglycinate chelate alginate iron deficiency anemia |
| url | https://www.mdpi.com/2072-6643/11/4/887 |
| work_keys_str_mv | AT lauragiancotti feralgineanewapproachforirondeficiencyanemiainceliacpatients AT valentinatalarico feralgineanewapproachforirondeficiencyanemiainceliacpatients AT giuseppeantoniomazza feralgineanewapproachforirondeficiencyanemiainceliacpatients AT santinamarrazzo feralgineanewapproachforirondeficiencyanemiainceliacpatients AT pietrogangemi feralgineanewapproachforirondeficiencyanemiainceliacpatients AT robertominiero feralgineanewapproachforirondeficiencyanemiainceliacpatients AT marcobertini feralgineanewapproachforirondeficiencyanemiainceliacpatients |